Patrick Spiering, MD
Family Medicine · Franklin, WINPI 1568578094
Payments from drug & device makers
Across 108 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$293
- AstraZeneca$264
- Lilly USA, LLC$122
- Ironshore Pharmaceuticals Inc.$113
- Boehringer Ingelheim$109
- Supernus Pharmaceuticals, Inc.$90
- plus $630 from 15 others
What the payments were for
- Food & beverage$1,56597%
- Education$563%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $293 |
| AstraZeneca | 16 | $264 |
| Lilly USA, LLC | 14 | $122 |
| Ironshore Pharmaceuticals Inc. | 12 | $113 |
| Boehringer Ingelheim | 8 | $109 |
| Supernus Pharmaceuticals, Inc. | 4 | $90 |
| AbbVie(2 entities) | 5 | $88 |
| Exact Sciences | 3 | $65 |
| Pfizer | 4 | $61 |
| Kowa Pharmaceuticals America, Inc. | 4 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $54 |
| Merck | 4 | $52 |
| GSK | 3 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Amgen | 2 | $35 |
| Astellas Pharma US Inc | 2 | $31 |
| Dynavax Technologies Corporation | 1 | $31 |
| Shire North American Group Inc | 2 | $25 |
| Johnson & Johnson | 2 | $25 |
| Shionogi Inc | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
How this compares
$1,621 in reported general payments places this provider in the 90th percentile of 1,482 family medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 221 | $248,369 |
| MounjaroTirzepatide | 112 | $120,854 |
| EliquisApixaban | 113 | $98,800 |
| JardianceEmpagliflozin | 77 | $94,241 |
| TrulicityDulaglutide | 49 | $67,057 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 50 | $57,075 |
| MyrbetriqMirabegron | 83 | $56,685 |
| XareltoRivaroxaban | 36 | $49,716 |
| Tresiba Flextouch U-200Insulin Degludec | 52 | $46,389 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 144 | $46,017 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $44,810 |
| FarxigaDapagliflozin Propanediol | 31 | $28,248 |
| JanuviaSitagliptin Phosphate | 29 | $26,558 |
| RybelsusSemaglutide | 12 | $15,879 |
| LinzessLinaclotide | 23 | $14,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $293 | $264,248233 claims |
| Lilly USA, LLCMounjaro, Trulicity | $122 | $187,911161 claims |
| PfizerEliquis, Abrysvo | $61 | $144,817257 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $109 | $101,09791 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta, Arnuity Ellipta | $40 | $78,658154 claims |
| Johnson & JohnsonXarelto, Invokana | $25 | $62,18851 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $37 | $57,07550 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $56,68583 claims |
| MerckJanuvia, Belsomra | $52 | $32,91843 claims |
| AstraZenecaFarxiga | $264 | $28,24831 claims |
| AbbVieLinzess | $88 | $14,72923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,482 family medicine providers in Wisconsin.
Other family medicine in Franklin
- Taha El-ShahatMadison$15.6M
- Jonathan MeimanMadison$4.3M
- John AgaibyKenosha$4M
- John LaabsShawano$3.6M
- Jennifer ParsleyElk Mound$1.4M
- William PalinMilwaukee$693K
- Jonathan TemteMadison$542K
- Ryan AndrewsStevens Point$429K
- Tara DallDelafield$230K
- Mark JensonGreen Bay$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.